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Abstract
Aims: Type 2 diabetes is highly prevalent in the elderly population. Glucagon like Peptide-1 mimetic such as exendin-4
augments post-prandial insulin secretion. However, the potential influence of aging on the therapeutic effects of this
peptide has not been well studied. In this study, we examined the glucose regulatory effects of exendin-4 in mice with
different ages.
Methods: We treated 3-month and 20 to 22-month old C57/DBA mice with 10 nM/kg exendin-4 for 10 days with
measurements of blood glucose and body weight. We performed OGTT and ITT to evaluate the glucose response and
insulin sensitivity. Islet morphology and beta cell mass were measured by immuno-staining and beta cell proliferation was
evaluated by BrdU incorporation and PCNA staining. Real-time PCR and western blot were used to measure protein changes
in the liver tissue after exendin-4 treatment.
Results: Exendin-4 treatment improved glycemic control in both 3-month and 20 to 22-month old mice. In both groups of
mice, the blood glucose lowering effect was independent of beta cell function as indicated by unchanged beta cell
proliferation, insulin secretion or beta cell mass. Moreover, we found that exendin-4 treatment increased hepatic AKT and
FOXO1 phosphorylation and inhibited glucose-6-phosphotase (G6P) and Phosphoenolpyruvate carboxykinase (PEPCK)
expression in young mice, but this effect was attenuated in aging mice while the insulin sensitivity showed no change in the
young group but significantly improved in aging mice.
Conclusion: Based on these data, we conclude that the glucose lowering effect of exendin-4 in normal non-diabetic mice
was not blunted by aging. We further showed that although there was slight difference in the glucose modulating
mechanism of exendin-4 therapy in young and aged mice, the improved glucose control seemed uncorrelated with
increased beta cell mass or insulin secretion.
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Introduction
Incretin based therapy has been clinically applied for the
treatment of diabetes. However, the glucose regulating mechanism
and potential danger are still less known and under hot discussion.
In this study, we used young and aging rodent models to evaluate
the potential effect of aging on Glucagon like peptide-1 (GLP-1)
mimetic exendin-4 therapy.
Exendin-4 is a DPPIV resistant GLP-1 receptor agonist [1].
Exendin-4 exerts insulinotropic effects and has multiple glucose
regulatory functions through activation of GLP-1 receptor in the
mammalian cells [2]. Exendin-4 treatment increases proliferation,
neogenesis and survival of beta cells through activation of PKA
and AKT with associated gene expression [3,4,5,6,7,8]. Treatment
with exendin-4 increases satiety, reduces food intake and slows
gastric emptying [9,10,11,12,13]. In adipocytes, exendin-4 en-
hances insulin sensitivity and glucose transport by increasing the
expression of Insulin Receptor beta (IR beta), Insulin Receptor
Substrate-1 (IRS-1) and Glucose Transporter 4 (GLUT4) [14,15].
In the murine liver, exendin-4 treatment improves glucose and
lipid metabolism[16], independent of insulin disposal although the
exact mechanism remains to be clarified [17]. It was also reported
that exendin-4 inhibited hepatocyte and cholangiocyte apoptosis
[18,19].
The risk of diabetes increases with age which is also a risk factor
for drug-induced hypoglycemia. Thus, GLP-1 mimetics may be
preferred in elderly subjects due to their low risk of hypoglycemia.
Despite these theoretical advantages, the effects of aging on
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function and proliferation decline with aging[20] and while the
GLP-1 mediated acute insulinotropic effect of exendin-4 is
maintained in adult and aged rodent, the drug has no effect on
beta cell proliferation [21,22]. With aging, there are also
downregulated key signaling molecules downstream of the GLP-
1 receptor, such as glucokinase, pancreatic and duodenal
homeobox 1 (Pdx-1), insulin and GLUT2 expression in the
pancreatic islets [23,24]. In this study, we systematically evaluated
whether the therapeutic effects of exendin-4 still maintain in aging
rodent models.
Previous studies on exendin-4 action were mostly done in
diabetic rodent models. Since beta cell function can be influenced
by prevailing blood glucose and lipid level as well as peripheral
insulin sensitivity, the blood glucose lowering effect of exendin-4
may be a non-specific effect due to amelioration of gluco- or lipo-
toxicity via improvement in the peripheral tissues. In this study, we
used mice with normal glucose tolerance to evaluate potential
infuence of aging on the glucose lowering effects of exendin-4.
Results
1. Exendin-4 improved glucose response in both young
and aging mice
Body weight and random blood glucose were not changed after
exendin-4 treatment in both groups of mice (Figure 1). However,
the OGTT test showed significantly improved glucose control in
both young and aging mice(Figure 1). However, the 24 hour food
and water intake was not altered by exendin-4 therapy in both
groups of mice, suggesting that the reduced food intake was not
responsible for the improved glucose response in exendin-4 treated
mice(Figure 1).
2. Insulin secretion was significantly lower in exendin-4
treated young and aging mice.
Exendin-4 increased beta cell mass and restored insulin
secretion in multiple diabetic models. Interestingly, according to
our data, although the OGTT showed significant improvement in
both groups of mice, the insulin levels during OGTT were
decreased by exendin-4 treatment in both young and aging mice.
This decline reached significance at 60 min in 3-months old mice
(Figure 2A). These data suggested that in the normal non-diabetic
mice, exendin-4 improved glucose control through an insulin-
independent mechanism.
3. Beta cell mass and proliferation were not changed in
either young or aging mice.
Exendin-4 has been reported to improve beta cell regeneration
and increase beta cell mass. However, in both 3-months and 20 to
22-months old mice, 10 days’ treatment with exendin-4 did not
significantly promote beta cell growth. The beta cell morphology
was normal and the beta cell mass were not changed in both
groups of mice. BrdU is a nuclear acid mimetic which is
incorporated into genomic DNA during cell proliferation. We
stained the pancreas with BrdU and insulin antibody and
quantified the ratio of BrdU positive cells in each islet of the
pancreas. In aging mice, the beta cell proliferation rate was very
low and showed no difference in both saline and exendin-4 treated
groups (Figure 3A). In the 3-month old mice, exendin-4 treatment
did not increase beta cell proliferation either. The quantification
results suggested a lower trend of proliferation rate in the islets of
exendin-4 treated group (Figure 3A),. The PCNA staining results
also showed no difference in 3-months old mice, in the aging
group, we failed to detect any PCNA positive cells in the
pancreatic islets, suggesting that the beta cell proliferation rate was
very low in aging mice (Figure 3B). In consistence with this result,
beta cell mass and islet area/whole pancreas ratio did not show
any increase by exendin-4 treatment in both young and aging mice
(Figure 3C).
4. Insulin sensitivity was slightly improved by exendin-4
treatment in aging but not young mice.
ITT was performed to evaluate the insulin sensitivity in young
and aging mice. After exendin-4 treatment, insulin sensitivity was
significantly improved in aging group But was not significantly
changed in young mice treated with exendin-4 (Figure 4).
The fasting glucose insulin and glucagon profile was evaluated
in both young and aging mice(Table.1). Based on the results, we
found that although blood glucose was not significantly different in
all four groups of mice, the insulin level was significantly increased
in aging group, suggesting enhanced insulin resistance in aging
mice.
The glucagon level was not significantly inhibited by exendin-4
in both groups of mice and in aging mice, serum glucagon level
was also significantly higher comparing with young mice (Table.1).
5. Exendin-4 inhibited glucose-6-phosphatase (G6Pase)
and phosphoenolpyruvate carboxykinase (PEPCK)
expression in the hepatocytes in young adult mice but
not aging mice.
Glucose homeostasis is mainly regulated through balanced
glucose output and uptake in the hepatocyte. As the improved
blood glucose response in both young and aging mice were not
accompanied by increased insulin secretion or beta cell mass, we
further checked the glucose metabolism in the liver by examining
the expression level of a series of genes participating in hepatic
gluconeogenesis and glucolysis in the exendin-4 treated mice. In
both 3 and 20 to 22-months old mice, glucokinase expression was
not changed by exendin-4. However, exendin-4 therapy inhibited
both G6Pase and PEPCK in 3-months old mice but in aging mice,
this effect was attenuated (Figure 5). The western blot results were
consistent with the real-time PCR data. These results suggested
that inhibited liver gluconeogenesis was at least partially involved
in the glucose lowering effect of exendin-4 in 3-months old but was
attenuated in aging mice.
6. AKT but not AMPK phosphorylation was activated by
exendin-4 in young but not aging mice
Both AMPK and AKT are key kinases which regulate glucose
metabolism in the hepatocytes. In our system, liver AMPK
phosphorylation was not altered by exendin-4 treatment. In
parallel with the G6P and PEPCK changes, AKT phosphorylation
level at both Ser473 and Thr308 sites were increased in exendin-4
treated young adult mice but not aging mice (Figure 6A). The
increased AKT phosphorylation was paralleled with enhanced
FOXO1 phosphorylation, a well established regulator of liver
gluconeogenesis (Figure 6A). The enhanced AKT phosphorylation
was not accompanied by upregulated insulin level with similar
fasting insulin levels in both groups of mice.
Discussion
In this study, we examined the effect of aging on therapeutic
responses of exendin-4 in 3-month and 20 to 22-month old C57/
DBA mice with normal glucose tolerance to examine whether
aging impaired exendin-4 therapy. After 10 days’ exendin-4
Aging and Exendin-4 Therapy
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glucose control. Increased insulin secretion might not be involved
in the glucose-regulatory effect of exendin-4 in our normal non-
diabetic model as insulin secretion level was not significantly
increased in both groups of mice after exendin-4 treatment. The
current data was consistent with our previous published results,
although exendin-4 treatment significantly increased beta cell
regeneration and improved glucose control in pancreatectomized
rats, the insulin level was actually substantially but not significantly
decreased by exendin-4 treatment [3]. This suggested that the
non-insulin effects of exendin-4 may also play a major glucose
modulating role. In both young and aging groups, the islet area
and beta cell mass were not altered by exendin-4 treatment. In
consistence, according to the in vivo BrdU incorporation assay and
PCNA staining results, the rate of beta cell proliferation was very
low in aging mice both in the PBS and exendin-4 treated groups,
while in the 3-months old mice, beta cell proliferation rate was
slightly but not significantly reduced after exendin-4 treatment.
This might be due to improved glucose response after exendin-4
treatment. In addition, in both young and aging mice, we did not
observe significant increase in AKT phosphorylation after
exendin-4 treatment (Figure S2).
Previous studies in young diabetic animal models suggested
exendin-4 augmented beta cell function. However, as beta cell
proliferation and insulin secretion were highly correlated with
circulation glucose and lipid, it is therefore difficult to identify the
non-beta cell effects due to improvement in glucose and lipid
profile. Also, it is not easy to clarify whether the increased beta cell
mass, which have been found in multiple diabetic rodent models
after exendin-4 treatment, was due to increased beta cell
proliferation or decreased beta cell apoptosis or both. In contrast
to the diabetic mice models, the non-diabetic mice showed normal
glycemic control and islet morphology with very rare TUNEL
positive cells in the panreatic islets (data not shown). In addition, as
beta cell proliferation rate is very low, it was reasonable that 10
days’ treatment was not enough to trigger obvious islet expansion
in normal adult mice. In support of this, we only found significant
increase in beta cell mass expansion 4 weeks after the exendin-4
intervention in the pancreatectomized rat model[3]. Indeed, in 2
months old mice, 21 days’ treatment with both 10 nM and 24 nM
Figure 1. Effect of exendin-4 treatment on body weight, blood glucose, food and water intake and glucose response in A,3 months
and B,20–22 months old mice, n=7 in each group of 3 months old mice, n=5 in each group of 20–22 months old mice. The values
were shown as Mean6SEM, **P,0.05 vs control group, ***P,0.01 vs control group.
doi:10.1371/journal.pone.0020443.g001
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but 10 days’ injection with both dosages showed no obvious
effect(data not shown),which suggested that exendin-4 only
triggered beta cell proliferation after relatively chronic treatment
in young mice. Therefore, 10 nM exendin-4 treatment for 10 days
in both young and aging mice was appropriate to study the extra-
pancreas effects of GLP-1 mimetics. This result is consistent with
previously published literature. [20].
Recently, the blood glucose lowering effects of exendin-4
independent of beta cells have attracted much attention. In in
vitro experiments, exendin-4 enhanced insulin signaling pathway
although it remains to be confirmed in in vivo conditions[25]. In
our experiment, the ITT results showed significantly improved
insulin sensitivity in aging mice but not in the 3-months old young
mice after exendin-4 treatment. This result was reasonable
because the insulin sensitivity in 3-months group was already
very ideal comparing to the aging mice. To explain how exendin-4
lowered glucose in those young adult mice, we checked the liver
glucose metabolism after exendin-4 treatment in 3 months old
mice. Liver is a major organ in maintaining glucose homeostasis
by balancing gluconeogenesis, glycogenolysis and glycogen
synthesis. In exendin-4 treated 3-month old mice, the liver
G6Pase and PEPCK expression level were decreased while that of
glucokinase was not altered. These results are consistent with
inhibition of hepatic gluconeogenesis with reduced glucose output.
The changes were accompanied by increased AKT activity, as
evidenced by elevation of ser473 and thr308 phosphorylation of
AKT as well as FOXO1 phosphorylation, but not AMPK. Since
FOXO1 positively regulates G6Pase and PEPCK transcription
[26,27], de-activation of FOXO1 by AKT may contribute to the
inhibition of gluconeogenesis by exendin-4 in these young mice.
These findings were not observed in the aging group. Previously
published findings from young or adult obesity models showed that
adenovirus mediated transduction of GLP-1 reduced liver glucose
output by inhibiting PEPCK and G6Pase expression in obese mice
[16,28,29], which is consistent with our current findings in young
mice. However, no studies were performed to evaluate the
therapeutic role of exendin-4 in aging obesity models. Comparing
with young mice, our aging mice were highly obese and insulin
resistant, which was close to young obesity rodent models in
phenotype. It is surprising that the liver response to exendin-4
seemed to be significantly blunted. The therapeutic effects of
exendin-4 in the liver of ageing mice need to be further explored.
In line withn our findings, in vitro activation of GLP-1R also
causes AKT phosphorylation in hepatocytes [28] although the
detailed mechanism is not fully elucidated. In the beta cells,
GLP-1R activation induces CREB phosphorylation with
upregulation of IRS protein expression and increased AKT
activity [30]. However, in our study, we did not find changes in
CREB-IRS signaling in the liver after exendin-4 treatment (data
not shown). Therefore based on our data, we can not get the
conclusion that the effect of exendin-4 in the rodent liver was
through the GLP-1 receptor. It has been suggested that GLP-1
receptor is uniquely expressed in the portal vein of the liver
organ and that hepatic glucose and lipid metabolism may be
regulated through a putative glucose/GLP-1 sensor in the
porto-hepatic circulation [31]. Other researcher proposed
expression of GLP-1R in both human hepatocyte tissue and
cell lines in the regulation of incretin effects in the liver [28].
However, the existence of GLP-1 receptor in rodent liver is still
very controversial. According to our data, the insulin secretion
level was not significantly altered by exendin-4 treatment, and
as the animals were sacrificed at least 12 hours after exendin-4
treatment, the insulinotrophic effect of exendin-4 could be
excluded. Therefore, the increased AKT/FOXO1 phosphory-
lation was less likely mediated by insulin. One explanation for
the in vivo effects of exendin-4 on the liver is the inhibited
glucagon secretion [32]. Therefore, we tested the serum
glucagon level in four groups of mice, the results showed that
although the serum glucagon level was significantly increased by
aging, it was not inhibited by exendin-4 treatment in both young
and aging mice. In addition, liver AMPK, which has been
reported to be phosphorylated by serum glucagon, was not
altered by exendin-4 treatment in both groups of mice[33].Th-
ese data suggested that glucagon might not participate in the
glucose modulating effect of exendin-4 in our models. Another
potential explanation is increased somatostatin. Somatostatin
secretion has been reported to be stimulated by exendin-
4[34,35,36]. The glucose modulating mechanism of somato-
statin based therapy was contraversial, several previous studies
showed that somatostatin normalized blood glucose potentially
by inhibiting glucagon secretion[37,38,39]. However in our
system, the glucagon level was not significantly altered.
Therefore increased somatostatin was less likely to participate
in the improved glucose response in our model. But we currently
do not have ELISA data to exclude this possibility.
Figure 2. Glucose stimulated insulin secretion in OGTT time points in A, 3 months and B, 20–22months old mice treated with PBS or
exendin-4, n=7 in each group of 3 months old mice, n=9 in each group of aging mice. Values were shown as Mean6SEM, **P,0.05 vs
control as determined by student t-test.
doi:10.1371/journal.pone.0020443.g002
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prevailing blood glucose level at least in the pancreatic islets of
human and rodents [40], it remains plausible that the inhibitory
effect of incretin therapy on hepatic gluconeogenesis might be due
to changes in other receptors or pathways yet to be identified.
Other researchers have shown that GLP-1 increased beta cell
proliferation by regulating IGF-1 receptor expression in the beta
cells [41]. Herein, interruption of IGF-1 receptor significantly
abrogated the proliferative and anti-apoptotic effects of GLP-1. As
AKT is one of the major kinases involved in IGF-1 receptor
signaling pathway, we also examined the expression of IGF-1
receptor expression in both groups of mice which remained
unchanged by exendin-4 treatment in both young and old mice
(data not shown). Taken together, we hypothesize that the
increased AKT phosphorylation in the liver might be mediated
through a signaling pathway different from that in the beta cells.
In aged rodent models with dysglycemia, GLP-1 infusion
augments insulin secretion and improves glycemic control [42,43].
However, beta cell proliferation capability was attenuated with
aging [9,21] and treatment with exendin-4 only caused minimal
mitosis in pancreatic islets of aged normal adult mice [21].
Moreover, latest evidence showed very rarely observed beta cell
proliferation and neogenesis in the human islets [44]. The age-
related phenomena might be due to downregulation of key
transcription factors and kinases implicated in beta cell survival
and mitosis [21,24,45]. In keeping with these findings, we also
observed very slow rate of beta cell proliferation in the aging mice.
Therefore, our findings and others suggest that the therapeutic
effects of exendin-4 mediated through beta cell regeneration might
not be clinically important in human adults. These evidence raised
the concern that the effect of incretin based therapy on the beta
cells might be affected by aging.
Figure 3. Beta cell mass and proliferation evaluation. Beta cell proliferation was evaluated by BrdU staining, the BrdU positive cells (red) to the
insulin secreting cell (green) ratio was quantified (Figure 3A). PCNA staining was performed in 3 months old mice and the PCNA positive cells (red) to
insulin secreting cell (green) ratio was quantified (Figure 3B). The beta cell mass and islet/pancreas % was also evaluated (Figure 3C) The values were
shown as Mean6SEM.
doi:10.1371/journal.pone.0020443.g003
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glucose-lowering effects of exendin-4 were preserved in aging non-
diabetic mice. These data strongly supported that although
exendin-4 mediated beta cell improvement might be affected by
aging, the non-beta cell derived glucose lowering effects of
exendin-4 therapy was still preserved, which maintained the
therapeutic response of exendin-4 in aging diabetic patients.
Exendin-4 reduced hepatic gluconeogenesis in young mice and
enhanced insulin sensitivity in old mice, both resulted in
normalized blood glucose. The lack of effects of exendin 4 on
GLP1 and IGF1 receptors also suggest that other novel pathways
may participate in the exendin-4 effect on the liver. These results
offer new insights into the age-related changes in glucose
metabolism which has bearing on the use of incretin-based
therapy in elderly population.
Methods
Animals and treatment
C57BL/DBA mice were maintained in a 12-h light/dark cycle
with free access to diet and water. Both 3-month and 20 to 22-
month old mice were treated with 10 nM/kg exendin-4 in
Phosphate buffered saline(PBS) or PBS alone by intraperitoneal
injection in the morning once daily for 10 days. 1 g/L BrdU was
added into the drinking water during the exendin-4 or PBS
treatment. Body weight and random blood glucose were measured
every two days. Oral glucose tolerance test (OGTT) was applied
on the 10
th day before exendin-4 treatment. After the OGTT test,
the mice will continue to receive exendin-4 or PBS injection on the
11
th day and sacrificed for tissue analysis on the 12
th day. All
procedures were in accordance with the guidelines for care and
use of laboratory animals and approved by The Animal Subjects
Committee of the Chinese University of Hong Kong.
Oral Glucose Tolerance Test (OGTT)
After 9 days of treatment, the mice were fasted for 12 hours
before OGTT. Each mouse was gavaged with 3 g/kg glucose.
Blood glucose was measured at 0, 30 60 and 120 min after
OGTT using One-touch Glucose Ultrameter (Johnson-
Johnson). The area under the curve (AUC) was calculated
using the formula AUC=0.256G0+0.56G1+0.756G60+
0.56G120 where G0, G30, G60, G120 were blood glucose
level at each time point during OGTT.
Insulin enzyme-linked immunosorbant assay (ELISA)
Fasting insulin and insulin secretion at each OGTT time point
were measured. Blood samples (about 100 ml) were collected from
the tail tips. This was achieved by cutting the tail tip of each mouse
Figure 4. Insulin Tolerance Test(ITT) in 3 months old mice and 20–22 months old mice. N=6 in each group of 3 months old mice and n=4
in each 20–22 months old mice. The Values were presented as Mean6SEM, *P,0.05 as determined by student test.
doi:10.1371/journal.pone.0020443.g004
Table 1. Glucose, insulin and glucagon profile in young and aging mice treated with PBS or exendin-4.
Young Aging
control exendin-4 control exendin-4
Fasting Glucose(mM) 7.4661.13 7.6560.86 6.2061.12 5.8060.98
Insulin (ng/ml) 0.4960.21 0.4860.23 3.9863.11
ab 1.6960.24
ab
Glucagon(pg/ml) 144.56619.85 191.71633.60 236.5564.68
ab 215.68639.89
ab
n=13 in each 3-months old group, n=9 in each aging group. a, p,0.05 vs young control; b, p,0.05 vs young exendin-4 as determined by Oneway-ANOVA test. The
values were shown as Mean6SEM.
doi:10.1371/journal.pone.0020443.t001
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tail tips into a heparinized capillary tube. The blood samples were
centrifuged at 4000 rpm at 4uC for 15 minutes and the
supernatant plasma was collected for insulin analysis. Plasma
insulin was measured using the rat/mouse insulin ELISA kit
(Millipore) according to the manufacturer’s instructions. Insulin
AUC was calculated by the formula AUC=0.256I0+
0.56I30+0.756I60+0.56I120 where I0, I30, I60, I120 were
insulin levels at each time point during OGTT.
Histological staining
Pancreatic islet morphology and BrdU incorporation were
quantified after treatment with exendin-4. Briefly, formalin fixed
and paraffin-embedded 4mm sections of pancreas were depar-
ifinized and dehydrogenated. After antigen retrieval, the sample
slides were stained with guinea-pig anti-insulin, rat anti-PCNA
(DAKO, 1:100), mouse anti-glucagon and rat anti-BrdU (Accurate
Chemical & Scientific, 1:200) overnight at 4uC, followed by
staining with cy2-goat anti-guinea pig, cy3-donkey anti mouse or
cy3-donkey anti-rat antibody (Jackson, 1:400) at room tempera-
ture for 2 hours. The sample slides were washed three times with
0.1% TBST and stained with DAPI (invitrogen) before micro-
scopic analysis. Insulin positive and BrdU positive cells in each islet
were quantified and BrdU+/Insulin+ ratio was determined to
evaluate beta cell proliferation in the pancreatic islets. The islet
and beta cell mass were determined as previously described[3].
Briefly, two pancreatic sections of each block were stained for each
animal. Insulin positive area vs total pancreas area was evaluated
using imageJ. The beta cell mass was quantified by multiplying the
pancreas weight with the insulin positive area.
Insulin Tolerance Test(ITT)
Insulin sensitivity was evaluated by ITT test after 9 days’
exendin-4 treatment. Briefly, all the mice were starved for 5 hours
before ITT. 1 IU/kg insulin was injected by ip and blood glucose
at 09,3 0 9,6 0 9 and 1209 was tested. AUC was calculated using the
formula AUC=0.256I0+0.56I1+0.756I60+0.56I120. I0, I30,
I60 and I120 represent the blood glucose at indicated time points.
Real-time PCR
Total RNA was extracted using the TRIZOL kit (invitrogen)
according to the manufacturer’s instructions. For real-time
quantification, the first strand cDNA was prepared using the
Reverse Transcription Kit (Invitrogen). The primers for real-time
Figure 5. Expression of Glucokinase, G6Pase and PEPCK level in young and aging mice treated with PBS or exendin-4. n=7 in each
group of 3 months old mice, n=5 in each group of aging mice. A, mRNA expression. B, protein level, the western blot was semiquantified. Values
were shown as Mean6SEM, ***P,0.01 vs control group as determined by student’s t test.
doi:10.1371/journal.pone.0020443.g005
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performed using the SYBR-Green Kit (ABI) on an ABI Prism
7000 and the expression results was normalized using beta actin as
internal control.
Western Blot
Proteins of the animal liver were analyzed by Western Blot. The
protein was separated in the SDS gel and transferred to the PVDF
membrane, which was further blotted with Ser473 and Thr305
Phospho-AKT, total AKT, Phospho-FOXO1 and total FOXO1
(Cell Signaling), Phospho-AMPK and total AMPK (Cell Signal-
ing), G6Pase (Santa Cruz), PEPCK and Glucokinase (Santa Cruz).
The density was analyzed by Image J and semi-quantified results
were presented.
Statistic Analysis
All data analysis was performed using SPSS 8.0, Comparisons
between control group and exendin-4 treated group were
evaluated by the Student’s t Test. All data was presented as mean
6 SEM. A P value ,0.05 was considered to be significant.
Supporting Information
Figure S1 21 days’ treatment of exendin-4 increased
beta cell proliferation. 2 months old mice were treated with
10 nM or 24 nM exendin-4 for 21 days. The beta cell proliferation
rate was measured using insulin(green) and BrdU(red) immuno-
fluorescent staining (A), the beta cell mass was measured(B) and
islet area was evaluated(C). n=3 in each group. **P,0.01 vs
control, ***P,0.001 vs control.
(TIF)
Figure S2 Double immuno-fluorescent staining for
insulin and AKT phosphorylation(Ser473) in the pancre-
atic islets. The pancreas of control and exendin-4 treated groups
were double stained with insulin(green) and P-AKT(red).
(TIF)
Table S1 Real-Time PCR primer sequences.
(DOC)
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